Management of post-chemotherapy residual masses in advanced seminoma

被引:63
作者
Fléchon, A [1 ]
Bompas, E [1 ]
Biron, P [1 ]
Droz, JP [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
关键词
testes; seminoma; drug therapy; cisplatin; neoplasm; residual;
D O I
10.1016/S0022-5347(05)64275-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases. Materials and Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients. Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes. Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend. to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.
引用
收藏
页码:1975 / 1979
页数:5
相关论文
共 21 条
[1]  
[Anonymous], 1997, J Clin Oncol, V15, P594
[2]   A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS [J].
BOSL, GJ ;
GELLER, NL ;
BAJORIN, D ;
LEITNER, SP ;
YAGODA, A ;
GOLBEY, RB ;
SCHER, H ;
VOGELZANG, NJ ;
AUMAN, J ;
CAREY, R ;
FAIR, WR ;
HERR, H ;
MORSE, M ;
SOGANI, P ;
WHITMORE, W .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1231-1238
[3]  
Culine S, 1998, EUR J CANCER, V34, P353
[4]   Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma [J].
De Santis, M ;
Bokemeyer, C ;
Becherer, A ;
Stoiber, F ;
Oechsle, K ;
Kletter, K ;
Dohmen, BM ;
Dittrich, C ;
Pont, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) :3740-3744
[5]   Radiotherapy after chemotherapy for metastatic seminoma - A diminishing role [J].
Duchesne, GM ;
Stenning, SP ;
Aass, N ;
Mead, GM ;
Fossa, SD ;
Oliver, RTD ;
Horwich, A ;
Read, G ;
Roberts, IT ;
Rustin, G ;
Cullen, MH ;
Kaye, SB ;
Harland, SJ ;
Cook, PA .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) :829-835
[6]   CHEMOTHERAPY OF ADVANCED SEMINOMA - CLINICAL-SIGNIFICANCE OF RADIOLOGICAL FINDINGS BEFORE AND AFTER TREATMENT [J].
FOSSA, SD ;
KULLMANN, G ;
LIEN, HH ;
STENWIG, AE ;
OUS, S .
BRITISH JOURNAL OF UROLOGY, 1989, 64 (05) :530-534
[7]   Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy [J].
Fossa, SD ;
Oliver, RTD ;
Stenning, SP ;
Horwich, A ;
Wilkinson, P ;
Read, G ;
Mead, GM ;
Roberts, JT ;
Rustin, G ;
Cullen, MH ;
Kaye, SB ;
Harland, SJ ;
Cook, P .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) :1380-1387
[8]   CISPLATIN, VINCRISTINE AND IFOSPHAMIDE COMBINATION CHEMOTHERAPY OF METASTATIC SEMINOMA - RESULTS OF EORTC TRIAL-30874 [J].
FOSSA, SD ;
DROZ, JP ;
STOTER, G ;
KAYE, SB ;
VERMEYLEN, K ;
SYLVESTER, R .
BRITISH JOURNAL OF CANCER, 1995, 71 (03) :619-624
[9]   THERAPEUTIC GUIDELINES AND RESULTS IN ADVANCED SEMINOMA [J].
FRIEDMAN, EL ;
GARNICK, MB ;
STOMPER, PC ;
MAUCH, PM ;
HARRINGTON, DP ;
RICHIE, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (10) :1325-1332
[10]   Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma [J].
Ganjoo, KN ;
Chan, RJ ;
Sharma, M ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3457-3460